Comparison of the efficacy and tolerability of Chondroitin plus Glucosamine and D-002 (Beeswax Alcohols) in subjects with osteoarthritis symptoms

Roberto Puente,1 José Illnait,1 Rosa Mas,2 Ernesto Lopez,1 Sarahí Mendoza,2 Daisy Carbajal,2 Lilia Fernandez, 2 Julio Fernández,2 Meilis Mesa,1 Pablo Reyes,3 Dalmer Ruiz 3

1 Surgical Medical Research Centre (Havana, Cuba) 
2 Centre of Natural Products, National Centre for Scientific Research (Havana, Cuba) 
3 Software and Database Group, National Centre for Scientific Research (Havana, Cuba) 

Correspondence to: 
Dra Sarahí Mendoza, PhD. 
Centre of Natural Products, National Centre for Scientific Research 
198 street and 19, Cubanacan, 
PO Box 6414, Havana, Cuba 
Phone number: (537) 2714200 
e.mail: clinica@enet.cu; sarahi.mendoza@cnic.edu.cu

Disclosure: No potential conflicts of financial interest relevant to this article were reported

Abstract

Background/Aims: Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile. D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.

Objectives: To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.

Methods: Participants were randomized to GS/CS (375/300 mg) or 50 mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the Visual Analogy Scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.

Results: Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.

Conclusions: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).

Key words (MeSH terms): D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score
Resumen
Antecedentes: La osteoartritis (OA), el desorden articular más común es causa principal de discapacidad. Las drogas SYSADOA (Symptomatic slow-acting drugs for OA), particularmente la combinación glucosamina/condroitín sulfato (GS/CS), son efectivas en el alivio de los síntomas, protegen el cartílago articular y retrasan la progresión de la OA, con un buen perfil de seguridad. El D-002, una mezcla de alcoholes de la cera de abejas que inhibe la actividad de las enzimas ciclooxigenasa y 5-lipoxygenasa, ha sido efectivo en estudios experimentales y clínicos, mostrando también efectos condroprotectores.

Objetivo: Comparar los efectos de la administración de D-002 y el GS/SC durante 12 semanas sobre los síntomas de la OA.

Material y Métodos: Los pacientes recibieron aleatoriamente GS/CS (375/300 mg/d) o D-002 (50 mg/d) por 12 semanas. La evaluación de los síntomas se realizó a través de las escalas WOMAC (Western Ontario and McMaster Individual Osteoarthritis Index) y la VAS (Visual Analogy Scale). La variable principal de eficacia fue la reducción de puntaje de la escala WOMAC. La variable secundaria incluyó los puntajes en los dominios dolor, rígidez y función física de la escala WOMAC, el puntaje de la escala VAS y el consumo de la medicación de rescate.

Resultados: De los 60 pacientes incluidos, 59 finalizaron el estudio. El D-002 y la combinación GS/SC redujeron significativamente el puntaje de la escala WOMAC (72.1% y 78.5%, respectivamente) y los puntajes de los dominios dolor, rígidez y función física versus el nivel basal. El puntaje de la escala VAS disminuyó significativamente en 76.6 % en el grupo D-002 y 76.8% en el grupo GS/SC. Las reducciones significativas alcanzadas desde la segunda semana se incrementaron en el transcurso del estudio. Utilizaron medicación de rescate 3/30 del grupo D-002 y 4/30 pacientes de los que recibieron la combinación GS/SC. No se encontraron diferencias significativas entre grupos. La tolerancia al tratamiento fue buena.

Conclusiones: El tratamiento con D-002 (50 mg/día) durante 12 semanas fue seguro y comparable al grupo que recibió GS/SC en el alivio de los síntomas de la OA (dolor, rígidez y limitación funcional) (RP-CEC00000180).

Palabras Claves: D-002, alcoholes de la cera de abeja, chondroitín sulfato, glucosamina, osteoartritis, puntaje WOMAC, Puntaje VAS.

Introduction
Osteoarthritis (OA), the commonest musculoskeletal disorder, is a leading cause of disability worldwide, mainly in the elderly. According to the increasing life expectancy, OA is expected to become the fourth leading cause of disability by 2020. OA is a progressive, painful and degenerative joint disease that affects every single tissue in the joint, characterized by localized cartilage loss, remodelling of adjacent bone and linked inflammation. OA management requires non-pharmacological and pharmacological approaches. While non-pharmacological is the pivotal treatment, it alone frequently is not enough for symptom relief and stopping OA progression. In turn, pharmacotherapy focuses on symptom relief with analgesics for pain, such as paracetamol, and non-steroidal anti-inflammatory drugs (NSAIDs) to treat both pain and associated inflammation. Analgesics and NSAIDs, however, are not only unable to solve the causal pathological process on the joint, but NSAIDs can produce gastrointestinal and cardiovascular adverse effects (AE), and paracetamol may cause hepatotoxicity. In light of these sounds, there is updated interest in the search for safer alternatives to long-term manage OA.
DOA) (glucosamine sulfate, glucosamine hydrochloride, chondroitin sulfate, hyaluronic acid, avocado soybean unsaponifiables, diacerein), second-line drugs for OA, improve the symptoms, decrease cartilage injury and are safer than NSAIDs and paracetamol for continuous or recurrent use. The discrepancies in the acceptance of SYSADOA in different OA guidelines, a matter influenced by many factors, may explain why their availability and prescription can considerably vary in different countries, so that a call for OA guidelines harmonization seems to be convenient. Various clinical trials have been conducted with SYSADOA. In particular, combined therapy with glucosamine (GS) plus chondroitin sulphate (CS) (GS/CS), has shown to produce symptom relief, protect joint cartilage and delay OA progression, with a good safety profile. A review of randomized trials, albeit most reported of low quality, concluded that short-term administration of chondroitin (alone or with glucosamine) was better than placebo in improving pain in OA patients. The benefit was estimated to be small to moderate, but clinically meaningful. Such efficacy, together with the low risk of their use, supports why these products are popular among OA sufferers. Despite some negative data and controversy around, moderate to high quality evidence supports that GS/CS produce pain reduction and physical function improvement in OA patients with good safety. GS/CS treatment given for 6 months has demonstrated comparable efficacy to celecoxib, a COX2 inhibitor, for reducing pain, stiffness, functional limitation and joint swelling in patients with painful knee OA. Hence, GS/CS is a good comparator for new substances of natural origin that pretend help in OA management.

D-002, a mixture of six high molecular weight aliphatic alcohols purified from beeswax, has demonstrated to inhibit both cycloxygenase (COX) and 5-lipoxygenase (5-LOX) activities in vitro. Oral administration of D-002 has been effective in experimental inflammation and in the model of moniodioacetate (MIA)-induced OA in rats, in which D-002 displayed chondroprotective effects, decreasing cartilage injury. Also, D-002 (50 mg/ day) given for 6-8 weeks reduced significantly OA symptoms and the need of using rescue medica-

Methods
Study design
This randomized, open, comparator (GS/CS) controlled study was approved by the Institutional Ethics Committee of the Surgical Research Centre (Havana, Cuba) and registered on the Cuban Public Registry of Clinical Trials (RPCEC00000180). The study was conducted according to the ethical standards of the Declaration of Helsinki. At enrolment, subjects provided their informed written consent after received, in a plain and understabler language, oral and written explanations about the purpose and details of the trial. Eligible patients were randomized, to GS/CS (375/300 mg) or 50 mg D-002 once daily for 12 weeks. Randomized subjects attended to visits every two weeks. Physical examinations, treatment compliance, symptom assessment, use of rescue medications and AE were controlled at each visit post-randomization. Laboratory examinations were done at baseline and after 6 and 12 weeks on treatment.

Study participants
The study enrolled ambulatory women and men (20 - 80 years) previously diagnosed of suffering knee, hip or finger OA, supported by clinical and radiological criteria. Participants should have a diagnosis of functional class I, II or III (mild to moderate) according to the American College of Rheumatology Criteria (ACRC) and a Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) ≥ 25. Exclusion criteria were other forms of arthritis, arthroscopy performed within the past year, intra-articular injection of steroids within the past 3 months, uncontrolled hypertension (diastolic pressure ≥ 120 Hg mm) or diabetes (fasting glucose > 7 mmol/L), active liver or renal disease, malignancies, any other serious illnesses, hospitalization during the 6 months prior to the study or the following laboratory abnormalities: alanine -ALT- and/or aspartate -AST-amino transferase>45 U/L, creatinine >130
µmol/L. Pregnant women, nursing women, and those not taking adequate contraceptive measures were also excluded.

Predefined premature discontinuations included unwillingness to follow-up, any AE supporting such decision and protocol violations (failure of tablets intake ≥5 days).

**Treatment**

Tablets of D-002 (50 mg) (Laboratorios MedSol, Havana, Cuba) and GS/SC (375/300 mg) (Aspen Pharma Pty Ltd, NSW, Australia) were used in the trial. The content of D-002 in the tablets was assessed by gas chromatography. Treatments were packaged in plastic bottles.

Eligible patients were randomly allocated to receive D-002 or GS/SC tablets. The tablets should be taken one per day with the breakfast for 12 weeks. The randomisation code was computer-generated with a fixed, not stratified randomisation method, using balanced blocks of 8 and allocation ratio of 1:1. The doses of D-002 have been used in previous clinical studies in OA patients.

Treatment compliance was controlled by counting the remainder tablets and interviewing the subjects. At study completion, non-used tablets were recovered. Compliance was considered good if the participants have taken at least 85% of the tablets scheduled from the previous visit.

Consumption of NSAIDs, steroids, cartilage or calcium supplements, or any other agent that may affect the study outcomes was forbidden, except that of rescue medications needed to treat persistent pain: acetaminophen (maximum 2 g/day) or metamizole (maximum 600 mg/day). Participants filled a daily record of their consumption of rescue medications, which was reported at each next scheduled visit, when the number of consumed rescue medication was recorded.

**Study outcomes**

The primary study outcome was a significant reduction of the total WOMAC index ≥30% as compared to baseline. The WOMAC questionnaire consists of three sections, one that assess pain intensity (5 questions), other joint stiffness (2 questions), and the third the physical function (17 questions). Individual responses were scored on the following scale: 0 (none), 1 (slight), 2 (moderate), 3 (severe) and 4 (extreme). The total score ranges from 0 (the best) to 96 (the worst). This tool provides a validated assessment of the patient's functional capacity, specifically joint pain, stiffness and functional impairment, being useful for the evaluation of the effect of investigation products on OA symptoms.

Significant decreases in pain, stiffness and physical function WOMAC scores, as well as in the Visual Analogy Scale (VAS) score (specific for pain) were secondary outcomes. In order to avoid biases, subjects answered to both WOMAC and VAS questionnaires in the doctor's office before their examination. The VAS-visual analogy scale score used a 100 mm linear measure of pain status with 0 representing no pain and 100 the worst suffered pain. Participants marked on the linear scale the relevant amount of pain they were suffering, and the value was noted.

Rescue medications use was another secondary outcome. The amount of rescue medication was assessed in terms of total use at study completion. All primary and secondary outcome measures were assessed at each visit.

The subjective self-perception of symptom relief at trial completion was a collateral outcome. This matter was assessed according to 4 options: very good (complete symptoms relief), good (remarkable symptom relief, but some symptoms still remaining), fairly (modest symptom relief) and poor (no symptom relief or worsening of symptoms).

**Safety and tolerability assessment**

Safety variables included physical (body weight, pulse rate, blood pressure) and blood indicators (alanine aminotransferase –ALT-, aspartate aminotransferase–AST-, serum fasting glucose, creatinine, cholesterol, triglycerides). Blood biochemistry indicators were assessed by using reagent kits (Roche, Switzerland) and performed in the Hitachi 709 autoanalyser (Tokyo, Japan).

Analyses were done at the clinical laboratory of the Surgical and Medical Research Centre (Havana, Cuba). Controls of the precision and accuracy of the methods were performed.

An AE was any undesirable event that newly appeared to a subject during the study, disregarding
the cause. At each visit subjects were queried about AE, which were recorded in case record forms, including their characteristics, dates of onset and disappearance, treatments adopted and responses achieved.

According to their severity, AE were classified as mild, moderate or serious. Mild AE were those easily tolerated so that did not require suspension of study treatments and/or specific intervention, moderate those that caused discomfort enough for requiring stopping therapy and/or specific intervention, and serious those disabling events leading to hospitalisation and/or deaths.

AEs that occurred within 30 days of consuming the last dose, monitored by direct contact with the subjects, were included in the analysis. The causal relationships between AEs and the treatments were classified by using the Naranjo algorithm.39

Statistical Analysis
Data were analysed as per the intention to treat approach. So, data of all randomized subjects were included in all analyses. The sample size estimation assumed a difference of 20% between the reductions of WOMAC total scores from baseline with each treatment at study completion. Then, 30 subjects per arm (60 participants) would be sufficient to detect such difference with 80% power and α = 0.05. Assuming a permissible dropout rate of 10%, 66 subjects were enrolled.

With the exception of the final value of the study withdrawal, there were not others missing data in the WOMAC and VAS scores. Continuous data were compared by using the Wilcoxon test for matched samples (comparisons within groups) and the Mann Whitney U test (between group comparisons). Bonferroni adjustment for multiple comparisons was applied.40 Categorical variables were compared with the Fisher Exact Probability test. All statistical tests for differences were 2-tailed. p<0.05 was considered for statistical significance. Comparisons were done by using the Statistics software for Windows (USA) and MS Excel. Statistical significance was taken at the 95% level (p<0.05).

Results
Baseline characteristics

Sixty-six (66) subjects were recruited for the study. Of them, 60 were eligible for randomization. Six subjects were not eligible because of having fasting glucose > 7 mmol/L (4 subjects) and a diagnosis of rheumatoid arthritis (2).

Baseline characteristics were well balanced in the two groups, so that treatment allocation was well randomized effective (Table 1).

Most study patients were women (53, 88.3 %), 49/53 postmenopausicas (92.5 %). Thirty one subjects (29, 48.3 %) were above the normal weight (25 just overweight, 4 obeses). The frequency of hypertension (35/60, 58.3 %), and hypercholesteraemia (31/60, 51.7 %) was also high (>50%), and the same was true for sedentary life (53/60, 88.3 %), a negative lifestyle factor. Smokers (3/60, 5 %), however, accounted for only 5% of study population. Consumption of concomitant therapy (59/60) was very high (98.3%). Of 60 randomized patients, 59 (98.3 %) completed the trial. One patient (D-002) withdrew from the study due to an AE (skin rash).

Adherence to study protocol was excellent, and treatment compliance was very good (≥90%) and similar in both study groups.

Efficacy analysis
Table 2 summarizes the effects on total WOMAC scores (mean ± SD).

The mean baseline total WOMAC scores were similar in two groups: 35.9 (D-002) and 36.8 (GS/SC). After 2 weeks on treatment D-002 and GS/SC reduced significantly (p<0.00001) the total WOMAC score by 44.6% and 40.2% as compared to baseline. Thereafter, the decreases of the total score were not only persistent, but increased, so that significant (p<0.00001) and marked reductions of 72.1% (D-002) and 78.5% (GS/SC) were seen at week 12. No significant differences between groups were found.

Both treatments decreased significantly pain (78.6% with D-002, 84.3% with GS/SC), stiffness (82.6% and 89.3%, respectively) and function (67.9% and 74.2%, respectively) WOMAC scores from the second week on therapy. The treatment effects did not wear off, but were enhanced during the trial.

The mean baseline WOMAC pain scores were
Table 1. Baseline characteristics of study population

<table>
<thead>
<tr>
<th></th>
<th>D-002 (n=30)</th>
<th>GS/SC (n=30)</th>
<th>Total (n=60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (X SD)</td>
<td>68 ± 7</td>
<td>67 ± 9</td>
<td>68 ± 8</td>
</tr>
<tr>
<td>Body mass index (kg/m²) (X ± SD)</td>
<td>25.2 ± 4.0</td>
<td>23.7 ± 4.0</td>
<td>24.4 ± 4.0</td>
</tr>
<tr>
<td>Total WOMAC scores (X ± SD)</td>
<td>n %</td>
<td>n %</td>
<td>n %</td>
</tr>
<tr>
<td>Women</td>
<td>28 93.3</td>
<td>25 83.3</td>
<td>53 88.3</td>
</tr>
<tr>
<td>Men</td>
<td>2 6.7</td>
<td>5 16.7</td>
<td>7 11.7</td>
</tr>
<tr>
<td>Degree of OA according to ACRC</td>
<td>I 0 0.0</td>
<td>3 10.0</td>
<td>3 5.0</td>
</tr>
<tr>
<td></td>
<td>II 23 76.7</td>
<td>20 66.7</td>
<td>43 71.7</td>
</tr>
<tr>
<td></td>
<td>III 7 23.3</td>
<td>7 23.3</td>
<td>14 23.3</td>
</tr>
<tr>
<td>OA diagnosis</td>
<td>Knee 28 93.3</td>
<td>29 96.7</td>
<td>57 95.0</td>
</tr>
<tr>
<td></td>
<td>Hip 20 66.7</td>
<td>22 73.3</td>
<td>42 70.0</td>
</tr>
<tr>
<td></td>
<td>Hand/fingers 21 70.0</td>
<td>25 83.3</td>
<td>46 76.7</td>
</tr>
<tr>
<td></td>
<td>Mixed 30 100.0</td>
<td>29 96.7</td>
<td>59 98.3</td>
</tr>
<tr>
<td>Main concomitant conditions</td>
<td>Hypertension 18 60.0</td>
<td>17 56.7</td>
<td>35 58.3</td>
</tr>
<tr>
<td></td>
<td>Hypercholesterolemia 13 43.3</td>
<td>18 60.0</td>
<td>31 51.7</td>
</tr>
<tr>
<td></td>
<td>Overweight (kg/m² ≥ 25, &lt; 30) 15 50.0</td>
<td>10 33.3</td>
<td>25 41.7</td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus 5 16.7</td>
<td>6 20.0</td>
<td>11 18.3</td>
</tr>
<tr>
<td></td>
<td>Thyroid dysfunction 4 13.3</td>
<td>3 10.0</td>
<td>7 11.7</td>
</tr>
<tr>
<td></td>
<td>Coronary heart disease (CHD) 3 10.0</td>
<td>1 3.3</td>
<td>4 6.7</td>
</tr>
<tr>
<td></td>
<td>Obesity (kg/m² ≥ 30) 2 6.7</td>
<td>2 6.7</td>
<td>4 6.7</td>
</tr>
<tr>
<td>Lifestyle factors</td>
<td>Sedentary life 29 96.7</td>
<td>24 80.0</td>
<td>53 88.3</td>
</tr>
<tr>
<td></td>
<td>Smoking 2 6.7</td>
<td>1 3.3</td>
<td>3 5.0</td>
</tr>
<tr>
<td>Concomitant therapy a</td>
<td>Consumers of at least one concomitant drug 29 96.7</td>
<td>30 100.0</td>
<td>59 98.3</td>
</tr>
<tr>
<td></td>
<td>Diuretics 9 30.0</td>
<td>11 36.7</td>
<td>20 33.3</td>
</tr>
<tr>
<td></td>
<td>Cholesterol-lowering drugs 8 26.7</td>
<td>12 40.0</td>
<td>20 33.3</td>
</tr>
<tr>
<td></td>
<td>Angiotensin converting enzyme inhibitors 7 23.3</td>
<td>8 26.7</td>
<td>15 25.0</td>
</tr>
<tr>
<td></td>
<td>β-blockers 7 23.3</td>
<td>2 6.7</td>
<td>9 15.0</td>
</tr>
<tr>
<td></td>
<td>Antiplatelet drugs 5 16.7</td>
<td>4 13.3</td>
<td>9 15.0</td>
</tr>
<tr>
<td></td>
<td>Oral hypoglycemic drugs 3 10.0</td>
<td>2 6.7</td>
<td>5 8.3</td>
</tr>
<tr>
<td></td>
<td>Calcium antagonists 2 6.7</td>
<td>3 10.0</td>
<td>5 8.3</td>
</tr>
<tr>
<td></td>
<td>Anxiolytics 2 6.7</td>
<td>3 10.0</td>
<td>5 8.3</td>
</tr>
</tbody>
</table>

SD standard deviation, OA osteoarthritis, ACRC American College of Rheumatology Criteria; a The table includes only those consumed by ≥5 subjects; No significant between group differences were found. (Mann Whitney U test, Fisher Exact Probability test for categorical variables)
Table 2. Changes in the total Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) scores

<table>
<thead>
<tr>
<th>Week</th>
<th>WOMAC Index scoresa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D-002</td>
</tr>
<tr>
<td>0 (baseline)</td>
<td>35.9 ± 5.1</td>
</tr>
<tr>
<td>2</td>
<td>19.9 ± 4.7 b</td>
</tr>
<tr>
<td>4</td>
<td>14.0 ± 7.8 b</td>
</tr>
<tr>
<td>6</td>
<td>14.4 ± 7.7 b</td>
</tr>
<tr>
<td>8</td>
<td>11.9 ± 7.3 b</td>
</tr>
<tr>
<td>10</td>
<td>12.3 ± 7.5 b</td>
</tr>
<tr>
<td>12</td>
<td>10.0 ± 6.9 b</td>
</tr>
<tr>
<td>% change</td>
<td>-72.1</td>
</tr>
</tbody>
</table>

Values are means ± SD, GS/CS glucosamine/chondroitin sulfate
a Divided into three domains: pain, stiffness and physical function.
Each domain has several items and each one is graded in a scale of 0 (none) to 4 (extreme), the lowest being the better, the highest the worst. There were a total of 24 items in the total WOMAC score
b p<0.00001 Comparisons versus baseline (Wilcoxon test for matched samples, Bonferroni adjustment)

11.2 (D-002) and 11.5 (GS/SC). At week 2 (first interim check-up), pain score had lowered significantly reduced with D-002 and GS/SC (p<0.00001 versus baseline for both comparisons). The effect was enhanced over the trial. At the end of the study the WOMAC pain scores lowered significantly to 2.4 (D-002) and 1.8 (GS/SC). In turn, the mean stiffness WOMAC scores decreased significantly (p<0.00001 versus baseline) from 2.3 to 0.4 (D-002), and from 2.8 to 0.3 (GS/SC), and physical function WOMAC scores lowered (p<0.00001 versus baseline) from 22.4 to 7.2 (D-002) and from 22.5 to 5.8 (GS/SC) (Table 3).

Table 3 lists the effects on the mean VAS score. After 2 weeks on treatment D-002 and GS/SC reduced significantly (p<0.0001) the VAS score versus baseline. The effects on VAS score, progressively enhanced thereafter, achieved percent decreases versus baseline of 76.6% (D-002) and 76.8% (GS/SC) at the end of the study.

The frequency of patients who required rescue medications (acetaminophen or metamizole) in each group (3 D-002, 4 GS/SC) was indistinguishable.

The assessment of the self perceived efficacy of treatments found that 12/30 (40%) and 9/30 (30%) of D-002 patients, respectively, classified the efficacy as very good and good, respectively, so that 21/30 (70%) was happy with the efficacy. In turn, 10/30 (33.3%) and 15/30 (50%) of the patients treated with GS/CS reported a very good and good efficacy, respectively, for a total of 25/30 (83.3%) cases who found that efficacy was satisfactory. Results in both groups were statistically comparable.

Table 3. Changes in pain, stiffness and physical function WOMAC scores

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Baseline</th>
<th>2 weeks</th>
<th>4 weeks</th>
<th>6 weeks</th>
<th>8 weeks</th>
<th>10 weeks</th>
<th>12 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain score a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-002</td>
<td>11.2 ± 2.2</td>
<td>5.8 ± 2.3 b</td>
<td>4.3 ± 2.6 b</td>
<td>4.0 ± 2.5 b</td>
<td>3.2 ± 2.3 b</td>
<td>3.0 ± 2.1 b</td>
<td>2.4 ± 2.2 b</td>
</tr>
<tr>
<td>GS/SC</td>
<td>11.5 ± 2.3</td>
<td>6.3 ± 2.9 b</td>
<td>4.0 ± 2.5 b</td>
<td>3.8 ± 2.8 b</td>
<td>2.9 ± 2.8 b</td>
<td>2.6 ± 2.4 b</td>
<td>1.8 ± 1.9 b</td>
</tr>
<tr>
<td>Stiffness score a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-002</td>
<td>2.3 ± 1.3</td>
<td>0.7 ± 0.7 b</td>
<td>0.5 ± 0.7 b</td>
<td>0.4 ± 0.6 b</td>
<td>0.4 ± 0.9 b</td>
<td>0.3 ± 0.7 b</td>
<td>0.4 ± 0.7 b</td>
</tr>
<tr>
<td>GS/SC</td>
<td>2.8 ± 1.5</td>
<td>1.4 ± 1.4 b</td>
<td>0.6 ± 0.7 b</td>
<td>0.4 ± 0.5 b</td>
<td>0.2 ± 0.4 b</td>
<td>0.5 ± 1.0 b</td>
<td>0.3 ± 0.6 b</td>
</tr>
<tr>
<td>Physical function a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-002</td>
<td>22.4 ± 3.8</td>
<td>13.3 ± 3.2 b</td>
<td>9.2 ± 6.1 b</td>
<td>10.0 ± 5.9 b</td>
<td>8.3 ± 5.6 b</td>
<td>9.0 ± 5.7 b</td>
<td>7.2 ± 4.9 b</td>
</tr>
<tr>
<td>GS/SC</td>
<td>22.5 ± 3.6</td>
<td>14.3 ± 5.2 b</td>
<td>8.3 ± 6.4 b</td>
<td>7.9 ± 6.0 b</td>
<td>7.2 ± 5.7 b</td>
<td>6.7 ± 7.7 b</td>
<td>5.8 ± 6.0 b</td>
</tr>
</tbody>
</table>

Values are means ± Standard Deviation, GS/CS glucosamine/chondroitin sulfate
a Measured on the following scale (0-4, where 0 = none, 1= slight, 2 = moderate, 3 = severe, 4 = extreme). The lowest the better, the highest the worst
b p<0.00001 Comparisons versus baseline (Wilcoxon test for matched samples, Bonferroni adjustment)
Safety and tolerability
Treatments were well safe and tolerated. Vital signs and blood parameters were not affected by the treatments, and individual values remained within normal ranges (data not shown for simplicity). There was only one study withdrawal (D-002), which was motivated by a moderate AE (skin rash) treated with topical corticoids. Other three subjects (1 in D-002 group, 2 in GS/SC group) referred some AE during the trial: urinary infection (D-002), heartburn (GS/SC) and stomach pain (GS/SC). No significant differences between the groups were noted.

Discussion
The progression of OA affects the quality of life of the sufferers.\(^1\) Pain decrease and improved function are the main objectives in OA management, which mainly involves medical treatment and lifestyle modifications. The consumption of NSAIDs for pain management in OA is highly frequent, but they increase the risk of gastrointestinal bleeding and cardiovascular adverse events.\(^4\)\(^ -\)\(^6\)
Second-line treatments (SYSADOA), not included in all guidelines, improve OA symptoms, reduce cartilage degradation, and have a better gastrointestinal profile as compared to NSAIDs, but the onset of their effects is more delayed.\(^12\)\(^ -\)\(^13\)
This study demonstrates that administration of D-002 (50 mg/day) and GS/SC (375/300 mg) for 12 weeks produce a significant improvement in the total WOMAC score, main study outcome, in patients with mild to moderate OA. Similar effects were seen on pain, stiffness, and physical function WOMAC scores, and on the VAS score for pain. The score decreases were significant from the first interim-check up conducted after concluding 2 weeks on therapy, and were enhanced throughout the study. The efficacy of both treatments was remarkable and comparable.
Since the two study groups were homogeneous at baseline, the randomized allocation of treatments should be accepted as adequate and the results here seen as attributable to the treatment, not to initial differences between them. The mean age of study population (68 years) is consistent with the fact that OA is a disease predominant in older people.\(^1\)\(^-\)\(^3\) The frequency of women (88.3%), higher than that of men (11.7%), agrees with the high frequency of OA reported in older women.\(^41\)
The high frequency of co-morbidities (overweight plus obesity, hypertension and hypercholesterolemia), and of lifestyle risk factors (sedentary life) between study subjects reflects the coexistence of concomitant coronary risk factors in middle-aged and older subjects with OA.\(^42\)\(^ -\)\(^43\)
Both treatments produced significant reductions of the total (main study outcome) and pain, stiffness and functional activity WOMAC scores (secondary outcomes), evident from the second week and enhanced thereafter. At study completion D-002 and GS/SC had decreased the total WOMAC score (72.1% and 78.5% versus baseline, respectively). In turn, the reduction of VAS score was also significant from the second week on treatment and increased progressively over the study, with final decreases of 76.6% (D-002) and 76.8% (GS/SC) versus baseline. The reductions of the WOMAC

### Table 4. Changes in VAS scores

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Baseline</th>
<th>2 weeks</th>
<th>4 weeks</th>
<th>6 weeks</th>
<th>8 weeks</th>
<th>10 weeks</th>
<th>12 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-002</td>
<td>64.0 ± 22.4</td>
<td>49.2 ± 21.0 b</td>
<td>42.3 ± 21.6 b</td>
<td>39.5 ± 23.1 c</td>
<td>30.0 ± 20.4 c</td>
<td>24.8 ± 18.2 c</td>
<td>15.0 ± 16.3 c</td>
</tr>
<tr>
<td>GS/SC</td>
<td>71.0 ± 23.7</td>
<td>58.2 ± 21.7 c</td>
<td>41.5 ± 22.4 c</td>
<td>38.3 ± 26.3 c</td>
<td>32.5 ± 25.2 c</td>
<td>28.5 ± 24.2 c</td>
<td>16.5 ± 15.2 c</td>
</tr>
</tbody>
</table>

Values are means ± Standard Deviation, GS/CS glucosamine/chondroitin sulfate

a Measured on a 100 mm scale of 0 to 100, where 0 = no pain and 100 was the worst possible pain
b p<0.0001; c p<0.00001 Comparisons versus baseline (Wilcoxon test for matched samples, Bonferroni adjustment)
pain and the VAS scores were grossly comparable. The decreases of all the scores were marked and comparable in the two groups. The decrease in pain was both clinically important and statistically significant (78.6% reduction with D-002 vs 84.3% with GS/SC), as was the improvement in stiffness (82.6% with D-002 vs 89.3% with GS/SC), and function (67.9% vs 74.2%, respectively). Similar reductions were seen in VAS (76.6% vs 76.8%, respectively), without differences between treatments. The decrease in pain was both clinically important and statistically significant (78.6% reduction with D-002 vs 84.3% with GS/SC), as was the improvement in stiffness (82.6% with D-002 vs 89.3% with GS/SC), and function (67.9% vs 74.2%, respectively). Similar reductions were seen in VAS (76.6% vs 76.8%, respectively), without differences between treatments. The efficacy of GS/CS on WOMAC scores here reported, however, is higher than that referred by other authors. A double-blind, randomized study found that GS (500 mg)/CS (450 mg) given three times a day for 6 months decreased significantly WOMAC pain (50.1%), stiffness (46.9%) and function scores (45.5%), similar to celecoxib 200 mg/day given once a day (50.2%, 49.2% and 46.4% reductions for WOMAC pain, stiffness and function scores, respectively; and 48.8% for VAS score). Since we used lower dose and shorter administration, the effect here seen (all reductions higher than 70%) are appreciably better, perhaps because our study was conducted in patients with mild to moderate symptoms, easier to control. In such regard, the efficacy of D-002 is consistent with that referred previously in subjects with mild to moderate OA. This study, however, had a duration (12 weeks) longer than that of previous studies of D-002 on OA (6 -8 weeks) basically because the comparator (GS/SC), albeit provided long-lasting pain relief and functional improvement in OA, has a slow onset of response as compared to NSAIDS. The mechanisms whereby D-002 and GS/SC may alleviate OA symptom are beyond the objective of this study. Nevertheless, GS and SC produce anti-inflammatory and chondroprotective effects involving the inhibition of metalloproteinase activity, prostaglandin E2 release, nitric oxide production and glycosaminoglycans degradation, and the increase of hyaluronic acid synthesis in the joint. CS stimulates collagen synthesis, whereas GS inhibits prostaglandin release, both substances together exhibiting synergic benefits. In contrast, D-002 inhibits COX and 5-LOX activities and produces a chondroprotective effect demonstrated experimentally. Interestingly, differently from the gastrototoxicity induced by NSAIDs, D-002 produces gastroprotection. The gastroprotective effect of D-002 involves the increased the secretion and improved composition of the gastric mucus, a defensive factor of the gastric mucosa, and the reduction of hydroxyl radical generation, lipid peroxidation and protein oxidation in the gastric mucosa. Administration of D-002 and GS/SC exhibited a good safety and tolerability, coherently with previous data on both treatments. The results of present study are extrapolable to patients with mild to moderate OA. Our data support that the efficacy and safety of D-002 is comparable to that of GS/SC in the management of these patients, and suggest that D-002 could be another alternative, mainly for patients who have contraindications for treatment with NSAIDs or paracetamol.

Conclusion
The present results, in addition to confirm the efficacy of D-002 and GS/SC in ameliorating OA symptoms, demonstrate, for the first time, that the efficacy and tolerability of the two treatments are comparable.

References


223.


